Want to join the conversation?
$VRTX 2Q15 Call: Since FDA’s approval of ORKAMBI, Vertex has been working to get the medicine to the approx. 8,500 eligible patients as rapidly as possible and its field teams have visited the vast majority of 275 CF centers in US, educating healthcare providers on ORKAMBI-prescribing information. As anticipated, interest in the medicine is high.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.